Walgreens Boots Alliance’s retail pharmacy business is on the rise, with the company’s CEO dismissing rumors of a potential buyout from private equity firms. The recent fiscal first quarter earnings report showed improvements in various aspects of the business, despite a wider net loss compared to the previous year. CEO Tim Wentworth emphasized the company’s focus on maintaining market share, strong returns in international markets, and progress in key areas essential for long-term success.
Analysts have taken note of Walgreens’ performance, with a more than 25% increase in stock price leading to increased market value. This surge has made it less likely for private equity firms to afford acquiring the iconic drugstore chain. While the company’s turnaround may still require more time and consistent execution of its strategy, analysts believe that patient long-term investors can expect significant upside in the medium term.
Walgreens is moving forward with its optimization plan, which includes ramping up store closures and selling its stake in the VillageMD primary care company. The plan aims to close about 1,200 stores over the next three years, with 70 closures already completed in the first quarter. Despite facing challenges such as soft retail sales, the company is making strides in its pharmacy, healthcare, and international segments.
Analysts like Rajiv Leventhal from Emarketer and Ann Hynes from Mizuho Securities USA have praised Walgreens’ performance in the first quarter of 2025. Leventhal believes that the commitment to a retail pharmacy-led operating model indicates a decreased likelihood of a sale to private equity. Hynes acknowledges the company’s progress but notes that retail sales remain a challenge that Walgreens must address.
Overall, Walgreens’ improving business outlook and strategic initiatives have instilled confidence in investors and analysts alike. While challenges persist, the company’s continued focus on operational efficiency and long-term value creation bodes well for its future prospects.
